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Background: The serum levels of IgG antibodies reactive to glycoconjugates (TF, Tn and αGal) were found to be associated with 
prognosis of gastrointestinal cancer patients. Aim: To study the relation between the levels of serum antibodies to TF-pAA, Tn-PAA 
and αGal-PAA polyacrylamide-based glycoconjugates and survival in breast cancer. Materials and Methods: The preoperative 
level of IgG antibodies was analysed in the serum of patients (n = 59) using ELISA with polyacrylamide-glycoconjugates namely, 
TF-pAA (amide-type), and ethanolamide-conjugates Tn-PAA and αGal-PAA. Survival rate and hazard ratio (HR) were assessed 
by the Kaplan — Meier method and Cox univariate analysis in different pathomorphological groups. Results: Significantly better 
survival was observed in patients with an increased level of anti-TF-pAA antibodies both for all patients in total and groups 
in stages II–III; N1–2 and G3 (p = 0.008–0.021, HR = 0.18–0.23, mean survival time in months 164–186 vs 69–121). A trend 
to worse survival was observed in increased level of anti-Tn IgG (stages II–III) and anti-αGal IgG (G3): p = 0.075, HR = 2.49 and 
p = 0.066, HR = 3.27, respectively. Conclusion: The method for the determination of circulating anti-TF-pAA IgG may be a use-
ful supplement in long-term prognostic assessment of patients with breast cancer.
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INTRODUCTION
Resident microbiota in h�mans colonizes bo�ndary 
s�rfaces maintaining imm�ne homeostasis [�]. Imba­
lance in microbial comm�nities� or microbial dysbiosis� 
has been shown to contrib�te to the cancero�s patho­
genesis and progression incl�ding breast cancer [�� 
�]. Microbial glycans are key antigens in host­microbial 
interactions [4]. Blood gro�p related cryptic glycans 
Thomsen — Friedenreich �TF� Galβ���GalNAcα�� Tn 
�GalNAcα� and αGal �Galα���Galβ� and/or mimicking 
determinants are present in enteric bacteria [5��]. 
Besides� TF and Tn are t�mor­associated glycans �TAG� 
beca�se they are freq�ently expressed in adenocarci­
nomas. The increased expression of TF and Tn is asso­
ciated with the t�mor invasion and metastases [����]. 
The αGal epitope is aberrantly expressed in h�man cells 
and it may be involved in a�toimm�ne diseases [�]. Be­
ing a constant so�rce of foreign antigens� microbiota 
stim�lates the prod�ction of anti­glycan antibodies. 
It is considered that the nat�ral anti­TF� ­Tn and ­αGal 
antibodies in h�man are ind�ced by enteric microorga­
nisms [5� �]. The high IgG antibody level and its change 
may reflect the adaptive imm�ne response of the host 
to microorganisms or increased a�toreactivity to self an­
tigens. Comparative data abo�t spontaneo�sly occ�r­
ring anti­glycan antibodies in cancer� their a�toreactivity 
to “self” and “altered self” antigens incl�ding TAG de­
serve a circ�mstantial investigation. We demonstrated 
the prognostic significance of the level of ser�m IgG 
antibodies to some glycans� and its relation to clinical 
parameters� t�mor progression and histopathological 
grading in gastrointestinal cancer patients [�����]. 
The antibody response to microbial glycans and its rela­
tion to s�rvival has not been chara cterized in patients 
with breast cancer yet. 
The aim of the present st�dy was to eval�ate whe­
ther the level of IgG antibodies to TF­pAA� Tn­PAA and 
αGal­PAA is related to s�rvival of patients with breast 
cancer� taking also into consideration the stage of the 
disease� t�mor vol�me� morphology and the t�mor 
spread in regional lymph nodes.
MATERIALS AND METHODS
Patients. The investigation was carried o�t in ac­
cordance with the ICH GCP Standards and approved 
by Tallinn Medical Research Ethics Committee� Esto­
nia. The informed consent was obtained from each 
patient �nder examination. Females with breast cancer 
in stages I�III �n = 59� whose diagnosis was verified 
by the pTNM system [�4]� were incl�ded in the st�dy. 
The chemo­ and X­ray therapy­prescribed patients 
as well as patients who died of ca�ses other than t�mor 
rec�rrence were excl�ded from the st�dy. The median 
and mean age ± SD was 5�.5 and 5�.� ± 9.4.
Glycoconjugates. The synthetic glycoconj�gates 
that are homogeno�s antigens with a single reiterative 
glycotope [�5] were obtained from Lectinity Holding 
Inc. The sol�ble TF conj�gate with  N­�ns�bstit�ted 
polyacrylamide �TF­pAA� amide­type� as well as etha­
nolamide­type glycoconj�gates of the poly[N­��­
hydroxyethyl�acrylamide] namely� Tn­PAA and αGal­
PAA �Bdi­PAA� were �sed in ELISA. The  TF­pAA con­
tained �.� mol of TF per � mol of pAA. The rest of the 
conj�gates had �.� mol of a saccharide per � mol 
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of PAA. Tris�hydroxymethyl�aminomethane­PAA was 
�sed as an adeq�ate negative control [��].
Indirect ELISA. The assay was performed as de­
scribed earlier [��]. The sera were kept at 4 °C for 
no longer than three weeks or were frozen �−5� °C� 
and thawed once before �se. The IgG antibody level 
was estimated as a ratio of Atest/Acontrol� where Atest is the 
absorbance with the glycoconj�gate and Acontrol� with 
the Tris­PAA. The variation coefficient was �%.
Isoelectric focusing (IEF) and Western blotting. 
IEF was performed in a �% agarose IEF �GE Healthcare 
Bio­Sciences AB� Sweden� containing ��% glycerol 
as described in [��]. A pH gradient was formed in the 
gel with 4% Ampholytes high resol�tion ���� �Sigma­
Aldrich� USA� and �% Pharmalyte 5�� �GE Healthcare 
Bio­Sciences AB� Sweden�.
Statistical analysis. The levels of antibodies were 
st�died in relation to overall s�rvival time  starting from 
the date of the preoperatively taken blood sample. 
The Kaplan — Meier method was �sed for the esti­
mation of s�rvival c�rves in the �nivariate analysis 
of patients gro�ps� the significance of differences was 
analyzed by the log­rank test. The Cox proportional 
hazards model was �sed to eval�ate the risk of death. 
Statistical analysis was performed �sing SPSS� ver­
sion ��.�. The median �M� of the level of anti­TF­pAA� 
­Tn and ­αGal antibodies was �sed as c�t­off to dis­
criminate between responders �R� the level above 
or eq�al to M� and weak responders �WR� the level 
below M�. S�rvival of R vs WR was eval�ated in s�b­
gro�ps divided by stages� t�mor vol�me� t�mor grade 
and regional lymph node metastases. The difference 
in s�rvival between patient gro�ps was considered 
to be significant when p ≤ �.�5.
RESULTS
Median and mean of the preoperative antibody 
le vels shown in Table � ranked as TF­pAA<Tn<αGal. 
Similar ratio of antibody levels was observed in gastro­
intestinal cancer patients and donors. The TF­R of dif­
ferent gro�ps demonstrated a significantly better s�r­
vival: p < �.�5� hazard ratio �HR� �.����.��� mean 
s�rvival time of R > WR �Table �; Fig. �� a�c�. The dif­
ference in s�rvival between TF­R and TF­WR in stages 
I�II and N� as well as in grades G��� or t�mor vo­
l�me T��4 was insignificant. The difference in s�r­
vival between Tn­R and Tn­WR as well as αGal­R and 
αGal­WR was insignificant for all patients or their patho­
morphological s�bgro�ps. A trend to a worse s�rvival 
of Tn­R and αGal­R �HR �.4���.��� in some s�bgro�ps 
was observed �Table �; Fig. �� d�.
Table 1. Median and mean of the antibody level in the serum of patients
Antibodies Median Mean ± SD, R Mean ± SD, WR
TF-pAA 1.255 2.999 ± 2.463 1.134 ± 0.063
Tn 1.805 3.913 ± 2.487 1.380 ± 0.236
αGal 3.790 6.293 ± 2.858 2.180 ± 0.790
The specificity of anti­TF­pAA antibodies affinity­
isolated from cancero�s sera was described ear­
lier [��]. In the present st�dy� we analyzed antibodies 
�sing IEF and the IgG­Western blotting and showed 
their polyclonal pattern �Fig. ��.
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Fig. 1. Probability of s�rvival in R �the level of ser�m antibodies 
above or eq�al to median M� a red line� vs WR �the level below 
M� a bl�e line�: a� b� c — the relation of the anti­TF­pAA IgG level 
to s�rvival; d — the relation of the anti­αGal IgG level to s�rvival. 
a — all patients; b — patients with an N��� stat�s; c� d — patients 
with G� t�mors
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Table 2. The relation of the antibody level in the serum of patients to survival
Anti-
bodies Group n p HR
Mean survival time,  
months and 95% CL*
TF-pAA All 56 0.012 0.22 185.8 (163.2–208.4) 
vs 121.2 (84.9–157.4)
Stages 
II–III
40 0.008 0.23 169.7 (136.8–202.6) 
vs 95.8 (56.7–134.9)
T2–4 36 0.062 0.30 168.1 (130.0–206.2) 
vs 100.3 (53.3–147.3)
N1–2 28 0.021 0.23 164.2 (123.1–205.3) 
vs 81.8 (38.1–125.6)
G3 25 0.017 0.18 167.5 (122.1–212.9) 
vs 68.7 (26.8–110.5)
Tn Stages 
II–III
42 0.075 2.49 108.3 (66.5–150.1) 
vs 157.9 (125.2–190.6)
αGal All 59 0.101 2.43 147.0 (115.0–178.9) 
vs 181.3 (160.8–201.7)
G3 27 0.066 3.27 98.4(40.4–156.3) 
vs 159.1 (121.1–197.2)
Note: *R vs WR. 95% confidence limit (CL) is lower and upper confidence 
limits shown in brackets. Breast cancer patients that were described in re-
ference [19] are also included in the Table
ba
Fig. 2. IEF and the IgG­Western blotting of samples affinity­
isolated from the ser�m of cancer patient: a — pAA­reactive 
antibodies isolated on TFα­spacer­Sepharose; b — pAA­reactive 
antibodies isolated on TFα­PAA­Sepharose. a and b correspond 
to samples � and � that described in [��]. The arrows show the 
difference in intensity of IgG­bands. The cathode on the top
DISCUSSION
We demonstrated earlier an association of the level 
of examined antibodies with s�rvival of patients with 
gastrointestinal cancer incl�ding pathomorphological 
s�bgro�ps. A significantly better s�rvival has been ob­
served in patients with an increased level of antibodies 
to TF­pAA and Tn­PAA while� on the contrary� a signifi­
cantly worse s�rvival was observed in an increased anti­
αGal­PAA IgG level or its postoperative elevation [��]. 
The present st�dy demonstrates an association of the 
ser�m level of anti­TF­pAA IgG and trend to associa­
tion of anti­Tn and anti­αGal IgG with s�rvival of breast 
cancer patients. Better s�rvival was revealed in an in­
creased level of anti­TF­pAA antibodies for all gro�p. 
Similar to patients with gastrointestinal cancer� a better 
s�rvival of TF­R was observed in s�bgro�ps of an ad­
vanced breast cancer and G� t�mor �see Table ��. Al­
tho�gh a significant differences for Tn­R vs Tn­WR and 
αGal­R vs WR were not fo�nd� val�es of HR>� and 
mean s�rvival time for s�bgro�ps presented in Ta­
ble � show a trend to worse s�rvival with an increased 
level of antibodies. The relation of anti­Tn and ­αGal 
antibodies level to s�rvival is less significant in breast 
cancer than in gastrointestinal cancer. The antibody 
response to some glycans of enteric microorganisms 
may be more informative for t�mors of digestive tract.
A low level of preoperative anti­TF­pAA IgG domi­
nated in stages III�IV of gastric cancer or in metastases 
N���� as well as in poorly differentiated carcinoma 
G� and it was �nfavorable indicator of s�rvival [��� �9]. 
Noteworthy� TF­WR in s�bgro�ps N��� and G� de­
monstrated worse s�rvival either in gastrointestinal 
or in breast cancer. The lower level of anti­αGal IgG 
has been associated with an advanced breast cancer. 
A significantly lower anti­αGal IgG was noted for gre ater 
t�mor size �T� + T� vs T�� and for stage II vs I as well 
as for low­differentiated breast carcinomas G� vs G� + 
G� [�9]. However� patients with G� t�mor and a lower 
level of anti­αGal antibodies �αGal­WR� were prone 
to longer s�rvival �see Table ��.
The low IgG reactivity to TF­pAA in patients with 
cancer may be d�e to the presence of ser�m factors 
that infl�ence the detection of antibodies. Nat�ral 
anti­glycan antibodies are mostly IgM­class antibo­
dies. IgM with corresponding specificities can compete 
with IgG for binding to glycan in ELISA and thereby 
red�ce IgG signal [��]. As a r�le� we observed a low 
IgM reactivity to TF­pAA in ser�m samples with a high 
corresponding IgG reactivity b�t inverse correlation was 
not revealed. No difference in s�rvival of gastric cancer 
patients was demonstrated in relation to the anti­TF­
pAA IgM level [��]. The other ser�m factor that can 
red�ce IgG binding to TF­pAA and thereby red�ce the 
signal of antibodies in ELISA is the TF­binding protein 
galectin �. Ser�m levels of galectin � in patients with 
breast and gastrointestinal cancer were significantly 
elevated especially in metastatic gastrointestinal carci­
noma as compared with healthy individ�als [��]. A high 
level of galectin � is associated with the worse s�rvival 
of colorectal cancer patients [��]. The increased level 
of galectin � in advanced cancer and its competition 
may be an additional factor improving eval�ation 
of s�rvival �sing determination of IgG reactivity �level� 
to TF­pAA. This s�pposition needs f�rther detailed 
investigations.
Anti­glycan antibodies belong to nat�ral antibo dies. 
Comm�nities of microbiota transmitted from mother 
to newborn remain stable in lifetime. The nat�ral IgG 
antibodies are also transferred from mother to fet�s 
and the repertoire of IgG a�toantibodies remains 
stable [��� �4���]. We observed a similar pattern 
of anti­TF­pAA� ­Tn and ­αGal IgG in sera of grand­
mother� mother and her ad�lt son; moreover� everyone 
of donors had a high level of anti­TF­pAA and anti­αGal 
IgGs. In most gastrointestinal cancer patients the an­
tibodies level is slightly changed b�t in some patients 
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we observed a high level of anti­glycan IgG and its 
postoperative elevation [��� ��� ��]. A very high level 
of anti­TF­pAA IgG was marked in eight long­term 
s�rvivors in stages II�III among ��4 patients �nder 
st�dy [��]. The twelve­fold change of the anti­TF­pAA 
IgG level was noted in the follow­�p. In one case the 
stable increase over the backgro�nd level co�ld be d�e 
to prolonged chemotherapy. The anti­TF­pAA IgG level 
correlated with a co�nt of blood lymphocytes and in­
versely correlated with ne�trophil/lymphocyte ratio [��� 
��]. Together these observations point to the adaptive 
anti­TF­pAA IgG response at least in some patients.
Anti­glycan antibodies associated with s�rvival may 
be involved in cancer progression thro�gh different path­
ways. Some of them are cross­reactive to histo­blood 
gro�p related antigens that may be aberrantly expressed 
in t�mors as prec�rsors or incompatible antigens [��]. 
Some genera of microbiota might express TAG­mimic 
antigens and stim�late TAG­a�toreactive antibodies� 
which may be beneficial or adverse for cancer patients.
To characterize the specificity of antibodies� anti­
TF­pAA IgGs were affinity­isolated from the ser�m 
samples of long­term s�rvivors� �sing different TFα­
conj�gated sorbents. Anti­TF­pAA IgG displayed a low 
specificity to the m�cino�s fraction isolated from 
malignant breast t�mors except three specimens [��� 
�9]. Affinity­isolated anti­Tn and ­αGal IgG also were 
low specific. The cross­reactivity of anti­TF­pAA IgG 
to different determinants incl�ding TFα­�nrelated 
reactivity and reactivity to the pAA carrier witho�t 
glycans was revealed. We renamed term �sed ear­
lier “anti­TF IgG” to “anti­TF­pAA IgG”. Antibodies 
were more reactive to TFβ �Galβ���GalNAcβ� than 
to TF �TFα� conj�gates� and they were a heterogenic 
pop�lation varying in the cross­reactivity to glycolipid­
related glycans with TFβ terminal resid�es� GA� and 
Gb5tri [��� ��� ��]� the latter being a terminal trisac­
charide of Gb5 �stage­specific embryonic antigen �� 
SSEA­��� which is expressed in ��.5% of breast cancer 
specimens [��]. The specificity to the pAA carrier and 
��%­TFα­pAA b�t not to the standart ��%­TFα­PAA� 
which was inherent in all IgG s�bpop�lations incl�ding 
those isolated witho�t carrier� is enigma [��]. These 
IgG s�bpop�lations belong to polyclonal antibodies 
�see Fig. ��. The pAA­mimic �glyco�peptide seq�ences 
of �nknown proteins may be nat�ral determinants for 
antibodies. The identification of nat�ral targets co�ld 
el�cidate the direct or indirect relation of a long­lasting 
anti­TF­pAA IgG imm�ne response to s�rvival.
Dysbiosis is associated with a breast cancer state 
and severity. The total bacterial DNA load was red�ced 
in the t�mor as compared to normal tiss�e and corre­
lated inversely with an advanced disease [�]. Dysbiosis 
may infl�ence the t�mor development via complex 
interrelations within the triad: resident microbiota — 
t�mor — imm�ne response in which some anti­glycan 
antibodies might be involved. The dynamic st�dy of the 
h�moral imm�ne response �sing glycomics together 
with microbial genomics can el�cidate interrelations 
leading to the carcinogenesis and t�mor progression.
CONCLUSIONS
The present st�dy demonstrates prognostic sig­
nificance of anti­TF­pAA IgG� which is acceptable not 
only for gastrointestinal cancer b�t also for breast can­
cer. The non­invasive screening test may be a �sef�l 
s�pplement in clinical o�tcome assessment.
ACKNOWLEDGEMENTS
This st�dy was s�pported by a grant № ��99 from 
the Estonian Science Fo�ndation.
REFERENCES
1. Arrieta MC, Finlay BB. The commensal microbiota 
drives immune homeostasis. Front Immunol 2012; 3: 33.
2. Xuan C, Shamonki JM, Chung A, et al. Microbial 
dysbiosis is associated with human breast cancer. PLoS One 
2014; 9: e83744.
3. Sheflin AM, Whitney AK, Weir TL. Cancer-promoting 
effects of microbial dysbiosis. Curr Oncol Rep 2014; 16: 406.
4. Stowell SR, Arthur CM, McBride R, et al. Microbial 
glycan microarrays define key features of host-microbial in-
teractions. Nat Chem Biol 2014; 1: 470–6.
5. Springer GF, Tegtmeyer H. Origin of anti-Thomsen-
Friedenreich (T) and Tn agglutinins in man and in white 
Leghorn chicks. Br J Haematol 1981; 47: 453–60.
6. Ju T, Otto VI, Cummings RD. The Tn antigen-structural 
simplicity and biological complexity. Angew Chem Int Ed Engl 
2011; 50: 1770–91.
7. Galili U, Mandrell RE, Hamadeh RM, et al. Interaction 
between human natural anti-alpha-galactosyl immunoglobu-
lin G and bacteria of the human flora. Infect Immun 1988; 
56: 1730–7.
8. Springer GF. Immunoreactive T and Tn epitopes 
in cancer diagnosis, prognosis, and immunotherapy. J Mol 
Med 1997; 75: 594–602.
9. Campbell BJ, Finnie IA, Hounsell EF, et al. Direct de-
monstration of increased expression of Thomsen-Friedenreich 
(TF) antigen in colonic adenocarcinoma and ulcerative colitis 
mucin and its concealment in normal mucin. J Clin Invest 
1995; 95: 571–6.
10. Yu LG. The oncofetal Thomsen-Friedenreich car-
bohydrate antigen in cancer progression. Glycoconj J 2007; 
24: 411–20.
11. Smorodin E, Sergeyev B, Klaamas K, et al. The rela-
tion of the level of serum anti-TF, -Tn and -alpha-Gal IgG 
to survival in gastrointestinal cancer patients. Int J Med Sci 
2013; 10: 1674–82.
12. Smorodin EP, Kurtenkov OA, Sergeyev BL, et al. Post-
operative change of anti-Thomsen-Friedenreich and Tn IgG 
level: the follow-up study of gastrointestinal cancer patients. 
World J Gastroenterol 2008; 14: 4352–8.
13. Smorodin EP, Kurtenkov OA, Sergeyev BL. The level 
of anti-(GalNAc beta) and anti-para-Forssman disaccharide 
IgG antibodies in patients with gastrointestinal cancer: relation 
to survival. Exp Oncol 2013; 35: 89–92.
14. Sobin LH, Gospodarowicz MK, Wittekind C, eds. 
TNM Classification of Malignant Tumours. 7th Edition. Wiley-
Blackwell, 2009. 336 p.
15. Bovin NV. Polyacrylamide-based neoglycoconjugates 
as tools in glycobiology. Glycoconj J 1998; 15: 431–46.
16. Smorodin EP, Kurtenkov OA, Sergeyev BL, et al. Anti-
bodies to tumor-associated carbohydrate epitopes in sera of can-
cer patients and blood donors. Exp Oncol 2001; 23: 109–13.
17. Smorodin EP, Sergeyev BL, Kurtenkov OA. The 
chara cterization of IgG antibodies to GalNAc beta-terminated 
glycans of gastric cancer survivors. Exp Oncol 2014; 36: 38–43.
Experimental Oncology ��� �������� ���� ���ne� ���
18. Smorodin EP, Kurtenkov OA, Sergeyev BL, et al. 
The characterization of cross-reactive antibodies to Thomsen-
Friedenreich a/b and related glycan-conjugates with polyac-
rylamide carriers in patients with gastrointestinal cancer. J Clin 
Cell Immunol 2011; S5.
19. Smorodin EP, Kurtenkov OA, Sergeyev BL, et al. 
The relation of serum anti-TF, Tn and alpha-Gal IgG antibody 
levels to cancer progression and histopathological grading. Exp 
Oncol 2002; 24: 270–3.
20. Muthana SM, Xia L, Campbell CT, et al. Competition 
between serum IgG, IgM, and IgA anti-glycan antibodies. 
PLoS One 2015; 10: e0119298.
21. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, et al. 
Humoral immune response to MUC1 and to the Thomsen-
Friedenreich (TF) glycotope in patients with gastric can-
cer: Relation to survival. Acta Oncol 2007; 46: 316–23.
22. Iurisci I, Tinari N, Natoli C, et al. Concentrations 
of galectin-3 in the sera of normal controls and cancer patients. 
Clin Cancer Res 2000; 6: 1389–93.
23. Barrow H, Rhodes JM, Yu LG. Simultaneous deter-
mination of serum galectin-3 and -4 levels detects metastases 
in colorectal cancer patients. Cell Oncol (Dordr) 2013; 36: 9–13.
24. Hanson LA, Korotkova M, Lundin S, et al. The transfer 
of immunity from mother to child. Ann NY Acad Sci 2003; 
987: 199–206.
25. Peterson CT, Sharma V, Elmén L, et al. Immune 
homeostasis, dysbiosis and therapeutic modulation of the gut 
microbiota. Clin Exp Immunol 2015; 179: 363–77.
26. Lacroix-Desmazes S, Mouthon L, Coutinho A, et al. 
Analysis of the natural human IgG antibody repertoire: life-
long stability of reactivities towards self antigens contrasts with 
age-dependent diversification of reactivities against bacterial 
antigens. Eur J Immunol 1995; 25: 2598–604.
27. Hakomori S. Antigen structure and genetic basis 
of histo-blood groups A, B and O: their changes associated with 
human cancer. Biochim Biophys Acta 1999; 1473: 247–66.
28. Smorodin EP, Kurtenkov OA, Sergeyev BL, et al. Specific-
ity of human anti-carbohydrate IgG antibodies as probed with poly-
acrylamide-based glycoconjugates. Glycoconj J 2004; 20: 83–9.
29. Smorodin EP, Kurtenkov OA, Sergeyev BL. The appli-
cation of human natural polyclonal IgG-antibodies to Thom-
sen-Friedenreich epitope (TFE) for evaluation of TFE-expres-
sion in cancer-associated mucins. Exp Oncol 2000; 22: 44–7.
30. Butschak G, Karsten U. Isolation and characterization 
of Thomsen-Friedenreich-specific antibodies from human 
serum. Tumor Biol 2002; 23: 113–22.
31. Chang WW, Lee CH, Lee P, et al. Expression of Globo 
H and SSEA3 in breast cancer stem cells and the involvement 
of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl 
Acad Sci USA 2008; 105: 11667–72.
Copyright © Experimental Oncology, 2016
